Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Non-GAAP R&D adjustments by Quarter
Non-GAAP R&D adjustments ($M) ($M)
Gilead Sciences Non-GAAP R&D adjustments: $335M in Q2 2026, up 717.1% from a year earlier.
Latest, Q2 2026
335
Period ended Jun 30, 2026
Change on a year earlier
+717.1%
41 in Q2 2025
History
39 quarters
Since Q4 2016
Sources
33
Documents cited below
Where the Q2 2026 figure comes from
“|| Research and development expenses adjustments | 335 | 41 | 352 | 81”
Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Reported in Form 8-K GAAP to Non-GAAP Reconciliation.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Gilead Sciences Non-GAAP R&D adjustments ($M), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/ng-adj-rd
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.